| Drug Name |
Atezolizumab |
| Drug ID |
BADD_D00179 |
| Description |
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy.[L7489] Atezolizumab was granted FDA approval on 18 October 2016.[L7489] |
| Indications and Usage |
For the treatment of patients with locally advanced or metastatic urothelial carcinoma who: 1) have disease progression during or following platinum-containing chemotherapy, and 2) have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. |
| Marketing Status |
Prescription |
| ATC Code |
L01FF05 |
| DrugBank ID |
DB11595
|
| KEGG ID |
D10773
|
| MeSH ID |
C000594389
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
50242-918; 50242-917; 12806-0917 |
| Synonyms |
atezolizumab | anti-PDL1 | immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer | MPDL3280A | MPDL-3280A | Tecentriq | RG7446 | RG-7446 |
